Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. - Wikidata - wikimedia - TriplyDB

Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots.

Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots.

http://www.wikidata.org/entity/Q33942207

about

Clinical relevance of immune monitoring in solid organ transplantation.Pre-transplant donor-specific T-cell alloreactivity is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving T-cell depleting induction therapy Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker.The influence of induction therapy for kidney transplantation after a non-renal transplant.Quantitative characterization of T-cell repertoire and biomarkers in kidney transplant rejection.Interferon Gamma ELISPOT Testing as a Risk-Stratifying Biomarker for Kidney Transplant Injury: Results From the CTOT-01 Multicenter Study.T-cell immune monitoring in organ transplantation.Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium Noninvasive methods to assess the risk of kidney transplant rejection.Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation.Immunologic monitoring in transplantation revisited.The application of monoclonal antibodies in cancer diagnosis.Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation.A New Window into the Human Alloresponse.Moving Biomarkers toward Clinical Implementation in Kidney Transplantation.Monitoring alloimmune response in kidney transplantation.Biomarkers to detect rejection after kidney transplantation.T-cell immune monitoring in organ transplantation.Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis.Characteristics of alloreactive T cells measured before renal transplantation.Alloimmune T cells in transplantation.Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.Detecting rejection after mouse Islet transplantation utilizing islet protein-stimulated ELISPOT

P2860

Q33509142-4FE0135D-3799-429E-B74B-878772569340 Q35092328-DFD09FF9-7E60-46D0-9244-861B1D18EA96 Q35580676-22EBAD8D-83E0-49E7-8423-0248AEB7A121 Q35692427-67B89480-0CE9-4943-B26B-3C6C2A1955FA Q36200173-8C112075-1A8A-4573-BDCC-07BACAA91B24 Q37097454-E9C1A1EE-0707-4996-8FA3-5CD9B43552F5 Q37236982-7D8D1BEE-5FA6-4343-88FE-49724D2B7D8F Q37339632-86715CB2-D6AA-4CE5-8618-A8CAB8E637EA Q37693693-C2940EF2-F542-4F9B-A887-F75A5D9A3E68 Q37939057-1BB57243-2BAC-4917-ABF6-471648D9E701 Q37970214-9F3275B6-252C-49F9-8544-D3986FC6A9BA Q38168870-1F6324BC-644C-4189-99BD-8FE9E3C3CA38 Q38202868-E69BEFEF-3911-4D5D-AD10-4C58CB32BF5C Q38694588-C4BF8592-2AFF-4CFB-B99E-34D710E72164 Q38773711-34AD85D1-7B66-432D-9896-9226DE350A80 Q38849321-CB18B3F9-8760-45CE-9153-9DD0BBA2669D Q39384930-81CECF7A-F28E-4AB4-9955-43FDF0ABC550 Q41947527-9AAA3FC5-D7B5-410E-92BF-86C60B41FE2B Q42213452-8FEC52EC-B4D3-4AA4-919B-5545B558A421 Q43838563-4E6C9D7C-8317-4BAD-9442-4DA8FB1BC30A Q50936985-723155C1-CB9F-420A-A10F-7CFFBE514262 Q52783253-CBBE6764-06AF-41C2-9A9C-C72A361EE867 Q56899161-89749F25-5607-4F13-9B89-EA1461DCDA41

P2860

Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots.

http://www.wikidata.org/entity/Q33942207

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Preferential benefit of antibo ...... me-linked immunosorbent spots.

@ast

Preferential benefit of antibo ...... me-linked immunosorbent spots.

@en

type

label

Preferential benefit of antibo ...... me-linked immunosorbent spots.

@ast

Preferential benefit of antibo ...... me-linked immunosorbent spots.

@en

prefLabel

Preferential benefit of antibo ...... me-linked immunosorbent spots.

@ast

Preferential benefit of antibo ...... me-linked immunosorbent spots.

@en

P1433

Q33942207-E0F74A3A-5987-4888-BA65-F73DD62EA66D

P1476

Q33942207-781D230A-E2D2-4A03-88E2-F5700E7A9E02

P2093

Q33942207-452C6FFE-60FB-4E60-8325-8C0D23905A31

Q33942207-90D40946-D9BE-4CC9-8DBD-8B6C029518C5

Q33942207-B70F0709-75EC-4D76-A8EB-0669FD7797C3

Q33942207-F1D38292-EFE3-4E19-A3C0-60D0BC7328B6

P2860

Q33942207-1D530411-3E7C-47C6-9179-7EDE091CD344

Q33942207-2C4A7DFD-9DC4-4CD6-AD27-55DA53401218

Q33942207-3CB05A74-EC52-44EC-9D19-A2ACAE10FE27

Q33942207-51AE14FB-7F3F-4916-95F5-F271838398CD

Q33942207-5B299930-7E85-4B24-B8EF-6D8A709E89FB

Q33942207-5EE0B594-654E-4E8B-8100-D6F69E507142

Q33942207-711CF6DE-5C6B-4ECE-961B-FF842B9FEE57

Q33942207-A3A25668-EF05-4167-8AD2-6F10D6CCE7F6

Q33942207-C9887ADE-F403-4188-B0AD-6E963D823403

Q33942207-C9BE7EBC-6A0A-4A01-A5BC-C7F64749A61C

P304

Q33942207-FEEE86A9-F095-4BD4-8803-C05A50C85AFD

P31

Q33942207-FD746E00-7B00-4E50-B7CB-2B76836D0660

P356

Q33942207-8F16A3D5-668F-4A9B-823B-2FE4FA37DCCA

P433

Q33942207-FD08AB30-0908-4192-9CCC-FF5D855BFCBA

P478

Q33942207-43A7A488-F6E2-4C55-8989-62F1170AE973

P577

Q33942207-C2E0AB4C-30A0-41B9-979C-160A5E81245B

P698

Q33942207-9198A596-3864-4B9F-9E90-E4ED42075783

P932

Q33942207-B8FDBFAA-7893-44B9-B364-7F38D016C7C5

P356

TP.0B013E31818046DB

P1433

Transplantation

P1476

Preferential benefit of antibo ...... me-linked immunosorbent spots.

@en

P2093

Donald E Hricik

http://www.w3.org/2001/XMLSchema#string

Emilio D Poggio

http://www.w3.org/2001/XMLSchema#string

Joshua J Augustine

http://www.w3.org/2001/XMLSchema#string

Peter S Heeger

http://www.w3.org/2001/XMLSchema#string

P2860

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group.

Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression.

Rabbit antithymocyte globulin versus basiliximab in renal transplantation.

Lack of economic benefit with basiliximab induction in living related donor adult renal transplant recipients.

Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes.

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

IL-2 is required for the activation of memory CD8+ T cells via antigen cross-presentation.

Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins.

Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion.

P304

529-534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/TP.0B013E31818046DB

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18724221

http://www.w3.org/2001/XMLSchema#string

P932

4108983

http://www.w3.org/2001/XMLSchema#string